**PROJECT SUMMMARY**

The HCC-ETN aims at developing a generic framework for comprehensive research on hepatocarcinoma (HCC) at the epigenetic, genetic, transcriptomic and metabolomic levels, in addition to the cell biology and virology levels, using human samples, and in vitro / in vivo models, in order to generate effective insight on HCC onset, pathogenicity and clinical targets identification.

As HCC is the best suited paradigm for cancer research (as a toxic- or infection- or genetics- or metabolics-driven disease), the HCC-ETN will allow ESRs to i) comprehensively tackle HCC challenges, and ii) benefit from a logically designed continuum from the molecular life sciences, to entrepreneurship knowledge & strategies, to medical humanities, maximizing long-term competitiveness and society benefits.

The HCC-ETN primary objectives are:

1. Improving general classification of HCC.
2. Identifying and validating novel drivers and suppressors of hepatocytic oncogenesis
3. Developing new treatment options following identification of driver mutations and their functional consequences
4. Exploiting the strong heterogeneity of HCCs etiologies and related features as an opportunity to launch broader collaboration across public and private bodies.
5. Educating and training young researchers with advanced knowledge and know-hows in order to satisfy tomorrow’s industrial needs and society demands thanks to the molecule-to-man spectrum described above
6. Disseminating key results through scientific publications and meetings, patients associations and Europe-wide scientific events and medias.

The HCC-ETN will train 15 ESRs bringing together 18 partners across HCC-relevant disciplines: structural biology, (epi)-genetics, transcriptomics, functional cell biology & imaging, and pathology from 7 European countries, including: 11 leading universities / academic research centers, and 7 biosciences corporations among which 1 world-leader industrial group, 1 medium-size industry and 5 SMEs.